CRTC2

Across TCGA pan-cancer cohorts, CRTC2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRTC2 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CRTC2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CRTC2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where CRTC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.889	0.674	<.001	46	view →
CCRCC	OS	Median	II,III,IV	0.889	0.581	.001	34	view →
LUAD	DFS	Tertile	All	0.731	0.374	.002	21	view →
LSCC	DFS	Tertile	III,IV	0.505	1.000	.008	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CRTC2–PDAC (DFS)

Open the PDAC breakdown →